問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

林信瓊
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

1Cases

2020-02-01 - 2023-12-15

Phase III

A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
  • Condition/Disease

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  • Test Drug

    ION-682884 Injection; Inotersen (ISIS 420915) Injection

Participate Sites
4Sites

Recruiting4Sites